Targeted therapies in the management of metastatic bladder cancer.

Authors

Matteo Fassan, Thomas Jefferson UniversityFollow
Edouard J. Trabulsi, Thomas Jefferson UniversityFollow
Leonard G Gomella, Thomas Jefferson UniversityFollow
Raffaele Baffa, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

12-1-2007

Comments

This article has been peer reviewed. It was published in: Biologics.

Volume 1, Issue 4, December 2007, Pages: 393-406.

The published version is available at PMID: 19707309 . Copyright © Dove Press.

Abstract

The management of metastatic urothelial carcinoma (UC) of the bladder is a common and complex clinical challenge. Despite the fact that UC is one of the most frequent tumors in the population, long term survival for metastatic disease remains low, and chemotherapy is curative for only a small minority of patients. UC is genetically heterogeneous, and it is surrounded by a complex tissue microenvironment. The problems of clinical practice in the field of metastatic bladder cancer have begun to stimulate translational research. Advances in the understanding of the molecular biology of urothelial cancer continue to contribute to the identification of molecular pathways upon which new therapeutic approaches can be targeted. New agents and strategies have recently been developed which can direct the most appropriate choice of treatment for advanced disease. A review of literature published on the targeted therapy for metastatic bladder cancer is presented, focusing on the molecular pathways shut down by the new therapeutic agents.

Recommended Citation

Fassan, Matteo; Trabulsi, Edouard J.; Gomella, Leonard G; and Baffa, Raffaele, "Targeted therapies in the management of metastatic bladder cancer." (2007). Department of Urology Faculty Papers. Paper 21.
https://jdc.jefferson.edu/urologyfp/21

PubMed ID

19707309